Transfer Factor: A Literature Course in Six Modules

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. It summarises what published papers examined and reported, and does not describe how any substance should be used.

Before Module 1: the phrase means two different things

Anyone reading the indexed literature on "transfer factor" runs into a naming collision almost immediately. One body of work uses the phrase for a biological preparation — low-molecular-weight material obtained from leukocytes or lymphoid tissue, often called dialyzable leukocyte extract. A second, much larger body of work uses transfer factor as an agricultural and radioecological ratio: the concentration of an element in a plant divided by its concentration in the soil the plant grew in. A third usage exists in respiratory physiology, where "transfer factor" is the European term for the lung's diffusing capacity; no paper in this course's verified reference set covers that usage, so it is noted only as nomenclature.

Both of the first two usages appear in the reference list below, and both are covered here, because a reader searching the term will encounter both. Nothing in one literature supports a claim in the other.

Module 1 — What it is, its class, origin and forms

The immunological preparation

The clearest orientation piece in the verified set is a review titled Transfer Factor: Myths and Facts, published in Archives of Medical Research in 2020, which framed the topic as one where claims and confirmed observations have historically diverged (PMID 32654883). The title itself is informative: the authors judged the field to contain enough unsupported assertion to warrant separating it from what is documented.

As a class, the material studied under this name is not a single defined molecule the way a synthetic peptide is. It is an extract. Origins described across the verified papers include human leukocytes and animal lymphoid tissue, and the forms differ by source organ and preparation route:

• Spleen-derived extracts. Researchers prepared transfer factor from chicken spleens in work on laying hens (PMID 36151767) and from spleens of reticuloendotheliosis virus–challenged chickens in a 2026 virological methods paper (PMID 41935579).
• Antigen-specific preparations made in vitro. A 2015 report described the preparation and identification of transfer factor specific to Staphylococcus aureus generated in vitro rather than from an immunised donor (PMID 24825752).
• Clinically applied extracts. A 2017 Brazilian surgical journal article addressed the use of transfer factor in immunosuppressed surgical patients (PMID 29019573).

The environmental ratio

In soil science and radioecology, transfer factor is a calculated, dimensionless number rather than a substance. Papers in the verified set applied it to caesium-137 and strontium-90 moving into crops in a semi-arid environment (PMID 33401155), to natural radionuclides and associated soil radiation hazard indices in crops (PMID 33942177), to soil-to-banana transfer in Lampung, Indonesia (PMID 40048929), to soil-to-plant transfer across six local government areas of Kwara State, Nigeria (PMID 39362113), and to arsenic uptake alongside growth-inhibition patterns in rice (PMID 29147882).

Limits of the evidence in Module 1

The verified record does not establish a standardised chemical identity, molecular weight specification or potency unit for the immunological preparation; each paper worked with material it prepared or sourced itself. Because the extracts differ by species, source organ and method, results from one preparation cannot be assumed to describe another. The environmental papers share a definition but not a value — transfer factors are site-, soil- and crop-specific by construction.

Module 2 — Mechanism as described in the literature

The historical premise behind the immunological preparation is that low-molecular-weight material from sensitised leukocytes can convey antigen-specific responsiveness to cells that had not previously encountered the antigen. The 2020 review examined which parts of this framework were supported and which persisted as assumption (PMID 32654883).

Two verified papers speak to mechanism indirectly by testing whether specificity can be engineered. The in vitro S. aureus work was designed around preparing and then identifying a transfer factor specific to a defined bacterial antigen, which places antigen specificity at the centre of the experimental question rather than treating it as settled (PMID 24825752). The chick study used spleen material from birds challenged with reticuloendotheliosis virus, again tying the preparation's source to a specific pathogen exposure (PMID 41935579).

Mucosal immunity appears as a separate mechanistic thread: the laying-hen study examined the effect of splenic transfer factor on development of the intestinal mucosal barrier, an endpoint that sits at the interface of gut structure and local immune tissue (PMID 36151767). An allergy-focused review considered the relationship between transfer factor and allergic disease, a different immunological axis again (PMID 21944489).

The environmental mechanism is entirely different and far less contested: uptake depends on soil chemistry, element behaviour and plant physiology, which is why the rice study paired transfer-factor profiles with growth-inhibition patterns under arsenic stress (PMID 29147882) and why radionuclide studies report values per crop and per location (PMID 33401155).

Limits of the evidence in Module 2

None of the verified immunological papers is a definitive mechanistic characterisation. The active constituent or constituents of a dialyzable leukocyte extract are not identified as a single defined entity anywhere in this reference set, and mechanism is therefore inferred from functional endpoints rather than from molecular pharmacology. A review that frames the field as "myths and facts" (PMID 32654883) should be read as a caution against treating any mechanistic account here as closed.

Module 3 — Reported outcomes, study by study

The table below lists what each verified paper studied and what its published record reported. No effect size, dose or duration is stated, because those figures are not available in the verified record used for this page.

Limits of the evidence in Module 3

The immunological outcome studies here are dominated by animal models — rats and poultry — and by reviews rather than large randomised human trials. A protective effect described in chicks (PMID 41935579) is a finding about chicks and a specific avian virus, not a statement about human disease. The single human-facing clinical article in the set concerns a narrow surgical population (PMID 29019573). No benefit in humans should be inferred from this collection, and the environmental papers contribute nothing at all to questions about human physiology.

Module 4 — Transfer Factor Side Effects: What Studies Report

Adverse-event reporting is the weakest part of this literature as represented in the verified set. No paper listed here is a dedicated safety or tolerability trial, and none of the records available for this page enumerates adverse events, frequencies or discontinuation rates.

What can be stated factually is where safety discussion would be expected to live. The 2020 review was constructed to separate substantiated statements about transfer factor from unsubstantiated ones, which is the closest thing in this set to a critical appraisal of the risk-benefit narrative (PMID 32654883). The surgical article dealt with an immunosuppressed population, the group in which tolerability questions carry the most weight (PMID 29019573). The allergy review addressed a condition in which hypersensitivity phenomena are the subject matter itself (PMID 21944489). Animal work in rat peritonitis (PMID 34527231) and in laying hens (PMID 36151767) reported on experimental endpoints rather than on human tolerability.

Limits of the evidence in Module 4

Absence of reported adverse events in a reference set of this size and design is not evidence of safety. Biological extracts derived from animal or human leukocytes raise general questions about immunogenicity, contamination and batch variability that the verified papers here do not resolve. Readers should treat the safety profile as undescribed rather than as favourable.

Module 5 — Pharmacokinetics, where data exist

For the immunological preparation, the verified set contains no pharmacokinetic study: no absorption, distribution, metabolism, elimination or half-life data appear in these records. That gap is structurally predictable, because pharmacokinetics requires a defined analyte to measure, and the reviewed material is an extract rather than a single characterised molecule (PMID 32654883). Work aimed at defining an antigen-specific preparation in vitro (PMID 24825752) illustrates that identification of the active material was still an active research problem.

The environmental literature has a quantitative framework that is sometimes mistaken for pharmacokinetics but is not: the transfer factor there is a steady-state concentration ratio between soil and plant tissue, computed per crop and per site, as in the banana study from Lampung (PMID 40048929) and the Kwara State survey (PMID 39362113). It describes uptake by plants from soil, not disposition of a drug in an animal.

Limits of the evidence in Module 5

Because no pharmacokinetic parameters are available in this reference set, no statement can be made about bioavailability by any route, duration of any effect, or accumulation. Anyone encountering such figures elsewhere should check whether they trace to a primary study or to marketing material.

Module 6 — Regulatory status, stated factually

This section describes general regulatory frameworks and is informational, not legal advice.

• Approved products. None of the verified papers describes a transfer factor product approved by a national drug regulator as a medicine for a stated indication. The preparations used in the studies listed were research preparations made or sourced by investigators, including spleen-derived material in poultry work (PMID 41935579) and in vitro antigen-specific material (PMID 24825752).
• Research-use-only material. Substances supplied for laboratory investigation are commonly labelled research use only, meaning they are not manufactured, tested or released to standards intended for administration to humans. Papers such as the rat peritonitis study operated in that research context (PMID 34527231).
• Clinical use reported in the literature. Use in patients has been described in the published record, including in immunosuppressed surgical patients (PMID 29019573). Publication of clinical use is a description of practice in a particular setting and is not itself a regulatory authorisation.
• Compounding. In the United States, compounding pharmacies operate under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; compounded preparations are not FDA-approved products and are not reviewed for safety, efficacy or manufacturing quality before distribution. Rules differ by country and by state.
• Consumer products using the name. The term also circulates on consumer products. The 2020 review's framing of myths versus facts is directly relevant to claims made outside the peer-reviewed record (PMID 32654883).

Limits of the evidence in Module 6

Regulatory status is jurisdiction-specific and changes over time; the verified papers were not written to document it, and none of them should be read as evidence that a given product is lawful, approved or appropriate anywhere.

What the studies did not test

Across the verified reference set, the following were not examined:

1. Dose-response in humans. No dose, schedule or treatment duration for human use can be cited from these records.
2. Long-term safety. No paper followed participants or animals for long-term outcomes or reported cumulative adverse events.
3. Head-to-head comparison with standard care. The animal studies in rats (PMID 34527231) and chicks (PMID 41935579) addressed experimental protection and treatment endpoints, not superiority to established therapies in people.
4. Product standardisation. Whether extracts from different sources are equivalent was not resolved; the in vitro specificity work indicates identification was still being developed (PMID 24825752).
5. Healthy-population use. The immunological studies used disease or challenge models, such as peritonitis in rats (PMID 34527231) and mucosal development in laying hens (PMID 36151767), not general use by healthy people.
6. Any human relevance of the environmental literature. Soil-to-plant transfer studies (PMID 33942177, PMID 33401155, PMID 29147882) concern crop contamination and radiological hazard assessment and have no bearing on immunology.

Readers comparing sources should note which meaning of "transfer factor" a paper uses before drawing any conclusion, and should bring questions about health decisions to a licensed clinician.

References

• Transfer Factor: Myths and Facts (Archives of Medical Research, 2020)
• Use of transfer factor in immunosuppressed surgical patients (Revista do Colegio Brasileiro de Cirurgioes, 2017)
• Transfer factor and allergy (Revista Alergia Mexico, 2010)
• Transfer factor treatment in management of peritonitis condition: An experimental study in rat (Annals of Medicine and Surgery, 2021)
• Preparation and identification of transfer factor specific to Staphylococcus aureus in vitro (Biotechnology and Applied Biochemistry, 2015)
• Effect of splenic transfer factor on the development of intestinal mucosal barrier in laying hens (Journal of the Science of Food and Agriculture, 2023)
• Transfer factor from REV-challenged chicken spleens enhances protection against reticuloendotheliosis virus infection in chicks (Journal of Virological Methods, 2026)
• Transfer factor of (137)Cs and (90)Sr to various crops in semi-arid environment (Journal of Environmental Radioactivity, 2021)
• The plant transfer factor of natural radionuclides and the soil radiation hazard of some crops (Environmental Monitoring and Assessment, 2021)
• Growth-inhibition patterns and transfer-factor profiles in arsenic-stressed rice (Oryza sativa L.) (Environmental Monitoring and Assessment, 2017)
• Soil-to-banana transfer factor of radionuclides in Lampung, Indonesia (Applied Radiation and Isotopes, 2025)
• Estimation of soil-to-plant transfer factor across six local government areas of Kwara state, Nigeria (Journal of Environmental Radioactivity, 2024)